Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience

Epidermal growth factor receptor (EGFR) gene mutations identify a molecularly defined subset of non-small cell lung cancer (NSCLC) patients who display an excellent sensitivity to EGFR tyrosine kinase inhibitors (TKIs). First-generation reversible EGFR TKIs, gefitinib and erlotinib have been proven...

Descripción completa

Detalles Bibliográficos
Autores principales: Ricciuti, Biagio, Baglivo, Sara, De Giglio, Andrea, Chiari, Rita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204616/
https://www.ncbi.nlm.nih.gov/pubmed/30355049
http://dx.doi.org/10.1177/1753466618808659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204616/
https://www.ncbi.nlm.nih.gov/pubmed/30355049
http://dx.doi.org/10.1177/1753466618808659

Ejemplares similares